What's new?Largest series of data published on clinical outcomes of a rotational lead extraction tool.The Evolution rotational extraction sheath shows a good safety and efficacy performance, especially in long implanted leads.The risk for superior vena cava injury when using the Evolution rotational extraction tool is very low.

Introduction
============

Transvenous lead extraction (TLE) plays an essential role in the long-term management of patients with cardiac implanted electronic devices. Fibrosis and calcification along implanted leads becomes increasingly likely with longer dwell times and simple traction is often not enough to achieve complete removal. Mechanical sheaths were the first widely used tool but were only moderately effective.[@euaa103-B1] Powered sheaths, utilizing either laser or radiofrequency energy to break down areas of fibrosis, were the next development. Of the two, laser powered sheaths gained the most traction and several large studies have shown them to achieve very high clinical success rates.[@euaa103-B2]^,^[@euaa103-B3] Concerns have been raised about the risk of major complications when using laser sheaths.[@euaa103-B1]^,^[@euaa103-B2]^,^[@euaa103-B4]

Rotational dissecting sheaths, characterized by a handle trigger-driven rotational dissecting tip at the end of a flexible sheath, have been available for this application for just over a decade.[@euaa103-B5] Rotational tools have been associated with greater efficacy than other non-laser methods in extracting all components of the targeted leads.[@euaa103-B6] Safety data from small case series have been promising,[@euaa103-B6] but data from larger series, such as that available for laser methods,[@euaa103-B3]^,^[@euaa103-B7] have been lacking. The range of rotational tools has continued to expand, as has the range of accessories for use in association with them to enhance safety and efficacy.[@euaa103-B6]^,^[@euaa103-B8]

To date, there is a lack of large volume data on advanced mechanical lead extraction techniques and tools. The PROMET (Patient-Related Outcomes of Mechanical lead Extraction Techniques) study was designed to address this by collecting data from consecutive patients treated in high-volume extraction centres in which rotational tools were the preferred method for TLE in cases not amenable to simple traction.

Methods
=======

Patient population
------------------

Patient data were collected from six European lead extraction centres that had maintained a comprehensive record of lead extraction procedures. Five of the six centres fulfilled the criteria of a high-volume extraction centre (\>30 procedures/year). Depending on the availability of sufficient data sets in different study centres and based on the retrospective design of this study, the starting point of data collection differed between the centres from as early as January 2005. The local review board at all investigational sites approved the research protocol. The results obtained were analysed retrospectively with regard to efficacy and safety.

Definitions
-----------

Success and failure were defined according to the definitions of the 2017 Heart Rhythm Society and the 2018 European Heart Rhythm Association expert consensus.[@euaa103-B12] In brief, complete success for the extraction of an individual lead was defined as the removal of all components of that lead from the vascular space without the occurrence of a fatal or permanently disabling complication. A procedure was considered a clinical success if it attained the intended clinical outcome and did not involve the retention of any lead portion \>4 cm in length.

Complications were adjudicated by a committee including representatives from each contributing centre. A complication was considered to have occurred if an undesired consequence of the extraction procedure suffering or disability, prolongation of the hospital admission, or a need for additional intervention or pharmacological therapy. Based on definitions *in prior* expert consensus papers,[@euaa103-B12] a complication was classed as serious if it led to the death of the patient or to persistent disability or if it required a substantial intervention such as cardiac surgery, pericardiocentesis, or vascular surgery. Fatalities were judged to be related to the extraction procedure if they occurred on the day of the procedure or as a consequence of a complication of the procedure.

Statistics
----------

Categorical variables are presented as numbers and percentages. Continuous variables are presented as mean ± standard deviation or as median and interquartile range (IQR), as appropriate. Differences between groups were analysed by two-sample *t*-test. A *P*-value of \<0.05 was considered significant.

Results
=======

Patient and lead characteristics
--------------------------------

Data were obtained for 2205 patients (69% male, age 66.0 ± 15.7 years; *Table [1](#euaa103-T1){ref-type="table"}*) with 3849 targeted leads for TLE. The mean dwell time of the targeted leads averaged 84.8 ± 61.9 months, with a median of 74 months (IQR 41--112). Seventy-five percent of the targeted leads were pacemaker leads, 25% implantable cardioverter-defibrillator leads.

###### 

Patient and lead characteristics

  Patient characteristics                
  -------------------------------------- --------------------------------
  Patient number                                       2205
  Age                                           66.0 ± 15.7 years
  Gender                                 
   Male                                                69%
   Female                                              30%
   Unknown                                              1%
  Left ventricular ejection fraction               38.3 ± 16.1%
  NYHA class (*n* = 187)                 
   Class 1                                            18.7%
   Class 2                                            25.1%
   Class 3                                            40.6%
   Class 4                                            15.5%
  Diabetes mellitus (*n* = 419)                       22.7%
  Chronic renal disease (*n* = 393)                   57.3%
  Cardiomyopathy (*n* = 542)             
   DCM                                                40.8%
   ICM                                                59.2%
  Previous cardiac surgery (*n* = 601)                27.8%
  Number of targeted leads                             3849
                                              74.8% pacemaker leads
                                                 24.6% ICD leads
                                          0.6% information not available
  Implant duration                       
   Mean implant duration                        84.7 ± 61.8 months
   Median implant duration                   74 months (IQR 41--112)
  Localisation of leads                  
   Right atrium                                    1167 (30.3%)
   Right ventricle                                 2238 (58.1%)
   Coronary sinus tributary                        395 (10.3%)
   SVC                                               8 (0.2%)
   Fragment or unknown                              41 (1.1%)
  Fixation mechanism                     
   Active fixation                                 1560 (40.6%)
   Passive fixation                                1795 (46.6%)
   Information not available                       494 (12.8%)

DCM, dilated cardiomyopathy; ICD, implantable cardioverter-defibrillator; ICM, ischaemic cardiomyopathy; IQR, interquartile range; NYHA, New York Heart Association; SVC, superior vena cava.

The most common indication for TLE was infection, present in 46%, but declined non-significantly over the course of the study, representing the primary indication in 47.0% in the first half of each centre's experience compared to 44.0% in the second half.

Techniques and equipment
------------------------

In all study centres a superior, subclavian approach was chosen as the primary option for lead extraction procedures. Most procedures (68.4%) were performed by cardiac surgeons, working in all cases in either a hybrid theatre (95.6%) or a standard operating theatre (4.4%). The remainder were performed by cardiologists/electrophysiologists, generally working in an electrophysiology laboratory (99.2%). All procedures not performed by a cardiac surgeon were performed with cardiac surgical stand-by including the availability of extracorporeal circulation and a perfusionist.

For leads that could not be extracted by simple traction, a multi-step lead extraction approach (individual to each study centre) was performed. A locking stylet (Liberator, Cook Medical, USA) was generally used as the first of these additional steps, making it the most commonly used item of specialized extraction equipment (*Figure [1](#euaa103-F1){ref-type="fig"}*). For 940 leads with a median dwell time of 71 months (IQR 48--93), the locking stylet alone allowed enough additional traction to remove the lead. In other cases, this traction permitted the use of the lead as a rail to guide an extraction sheath.

![Temporal trends in the equipment used in the PROMET cohort. Laser equipment was almost abandoned by all centres within the first half of the experience. There was increasing uptake of rotational dissection sheaths instead of traction-only or laser methods, with a high and constant background usage of locking stylets.](euaa103f1){#euaa103-F1}

Dissection sheaths included simple polypropylene models (Byrd Dilator Sheath, Cook Medical, USA), PTFE sheaths (Cook Medical, USA), laser sheaths (SLS II, Philips, USA), and rotational tools (Evolution and Evolution RL, Cook Medical, USA; Tightrail, Philips, USA). Laser sheaths were used for 139 leads (3.6%) with a median dwell time of 57 months (IQR 38--81). Their use was confined to the first half of the case series and they were used in only three centres, accounting for 21% of leads extracted in one centre, fewer than 1% in the other two.

Where a subclavian approach failed or was expected to be impossible, a femoral or an internal jugular approach was performed. In these cases, a variety of snares were used, predominantly the Needle's Eye (Cook Medical, USA) which accounted for 70% of all snare usage.

Safety
------

Major complications occurred in 22 cases (1.0%; *Table [3](#euaa103-T3){ref-type="table"}*, *Figure [2](#euaa103-F2){ref-type="fig"}*), and minor complications in 3.1%. Procedure-related mortality occurred in four patients (0.18%), three of whom had systemic infection as the indication for extraction.

![Safety endpoints of the PROMET study in the overall cohort and in the subset in whom rotational dissection sheaths were used.](euaa103f2){#euaa103-F2}

###### 

Major complications

  Patient details    Device and lead number                                             Indication                                            Dwell time of oldest lead (months)   Equipment used                                                  Complication and treatment                                                                              Outcomes
  ------------------ ------------------------------------------------------------------ ----------------------------------------------------- ------------------------------------ --------------------------------------------------------------- ------------------------------------------------------------------------------------------------------- -------------------------------------------------------------
  80 years, male     Dual chamber pacemaker                                             Infection                                             124                                  Locking stylet, simple sheath                                   Cardiac avulsion                                                                                        Full recovery after surgical repair
  83 years, female   Single chamber pacemaker                                           Infection                                             151                                  Locking stylet, simple sheath                                   Pericardial effusion, percutaneous drainage                                                             Full recovery
  37 years, female   Dual chamber pacemaker with abandoned leads (4 leads total)        Infection, local                                      228                                  Locking stylets, femoral snare (needle eye)                     Pericardial effusion post-procedure, percutaneous drainage                                              Full recovery
  77 years, male     Dual chamber pacemaker                                             Redundant lead                                        178                                  Locking stylet, Evolution (13F), femoral snare (needle eye)     Cardiac avulsion during use of femoral snare                                                            Surgical repair, but died within 30 days
  65 years, female   CRT-D                                                              Lead failure                                          141                                  Locking stylet, simple sheath, Evolution                        Right ventricular injury                                                                                Full recovery after surgical repair
  46 years, male     Dual chamber pacemaker                                             Systemic infection                                    47                                   Locking stylet                                                  Pericardial tamponade                                                                                   Full recovery after surgical repair
  83 years, female   Dual chamber pacemaker with abandoned leads (total 4 leads)        Infection                                             \>120                                Evolution, femoral snare                                        Pericardial effusion                                                                                    Uncomplicated recovery after percutaneous drainage
  88 years, female   Dual chamber pacemaker (2 leads)                                   Perforated lead, lying in pleural space               2                                    Locking stylet                                                  Oesophageal injury from transoesophageal echo probe                                                     Recovered after long hospital stay
  80 years, female   Dual chamber pacemaker (2 leads)                                   Infection                                             285                                  Locking stylet, compression coil, Evolution RL (11F)            Peri-procedural stroke                                                                                  Recovered
  43 years, male     Dual chamber ICD with abandoned leads (3 leads)                    Infection                                             66                                   Evolution                                                       Pericardial tamponade                                                                                   Full recovery after surgical repair
  47 years, female   Single chamber ICD                                                 Lead malfunction                                      59                                   Evolution RL                                                    Right pleural collection of blood drained percutaneously at 1 day after extracting right sided device   Full recovery. No surgery, no transfusion required
  78 years, female   Dual chamber PPM                                                   Local infection                                       Unknown                              Locking stylet, compression coil, Evolution RL (11F)            Injury to right ventricle                                                                               Full recovery after surgical repair
  75 years, female   CRT-P (including Starfix lead)                                     Lead malfunction                                      15                                   Locking stylet, compression coil, Evolution RL (9F)             Injury to coronary sinus                                                                                Full recovery after surgical repair
  63 years, male     CRT-D                                                              Lead malfunction                                      83                                   Locking stylet, compression coil, Bulldog, Evolution RL (13F)   Injury to inferior vena cava causing pericardial tamponade                                              Full recovery after surgical repair
  74 years, male     Dual chamber PPM, abandoned leads (total 4 leads)                  Venous occlusion, redundant leads, need for upgrade   356                                  Locking stylets, Evolution 9F                                   Pericardial tamponade due to RV perforation                                                             Full recovery after surgical repair
  78 years, female   Dual chamber pacemaker                                             Local infection                                       Unknown                              Liberator, compression coil, Evolution 9F                       Tamponade due to RV perforation                                                                         Full recovery after surgical repair
  79 years, male     CRT-D with redundant leads (total 7 leads)                         Septicaemia                                           79                                   Liberator, compression coil, Evolution RL 13F                   Septic shock                                                                                            Peri-procedural death
  37 years, male     Dual chamber ICD                                                   Lead malfunction                                      83                                   Simple stylet                                                   Pericardial tamponade                                                                                   Full recovery after surgical repair
  83 years, female   CRT-D                                                              Local infection                                       126                                  Liberator, compression coil, Evolution RL 13F                   Pericardial tamponade                                                                                   Initial recovery after surgical repair, but died at 30 days
  65 years, male     CRT-D                                                              Systemic infection                                    105                                  Liberator, compression coil, Evolution RL 13F                   Left-sided haemothorax                                                                                  Full recovery after surgical placement of a chest drain
  61 years, female   Single chamber pacemaker with redundant leads (3 leads in total)   Septicaemia                                           208                                  Liberator, compression coil, Evolution RL 13F                   Injury to junction of SVC and RA leading to pericardial tamponade                                       Died at 2 days post-procedure despite surgical repair
  48 years, male     Single chamber ICD                                                 Systemic infection                                    4                                    Liberator, compression coil, Evolution RL 13F                   Damage to tricuspid valve requiring subsequent valve surgery                                            Full recovery after surgical repair

CRT-D, cardiac resynchronization therapy with defibrillator; CRT-P, cardiac resynchronization therapy pacemaker; ICD, implantable cardioverter-defibrillator; PPM, permanent pacemaker; RA, right atrium; RV, right ventricle.

Efficacy and efficiency
-----------------------

Among the entire study group (2205 patients/3849 leads), complete technical success was obtained in the extraction of 96.5% of leads, with a clinical success rate of 97.0% of procedures.

Rotational dissection tools
---------------------------

Subgroup analysis was performed for the use of the Evolution or the Evolution RL rotational TLE devices, which were used for 1552 leads in 992 patients. Other devices of the Evolution group including the Evolution Shortie, the Evolution Shortie RL, and the Evolution outer sheath were not included unless used in association with the full-length Evolution or Evolution RL. The Tightrail rotational extraction sheath was not included as the design of this tool is substantially different, and the device was used for only 12 leads.

Leads removed using the Evolution rotational tools had a longer dwell time than others (*Table [2](#euaa103-T2){ref-type="table"}*, *Figure [3](#euaa103-F3){ref-type="fig"}*). Despite the implant duration of the leads extracted in the Evolution group, complete procedural success was only 2.1% lower than in the non-Evolution group (95.2% vs. 97.3%).

![Complete procedural success in per lead extracted, according to the method used to extract the lead.](euaa103f3){#euaa103-F3}

###### 

Subgroup analysis of cases with the use of the Evolution rotational sheath vs. cases without Evolution

                                            Evolution-group (992 patients/1552 leads)   Non-Evolution group (1213 patients/2297 leads)  *P*-value
  ---------------------------------------- ------------------------------------------- ------------------------------------------------ -----------
  Median implant duration                           106 months (IQR 66--145)                        58 months (IQR 28--90)              \<0.001
  Complete procedural success (per lead)                      95.2%                                         97.3%                       0.003
  Major complications                                         1.6%                                           0.5%                       \<0.01
  Procedure-related mortality                                 0.4%                                            0%                        \<0.05

IQR, interquartile range.

The major complications encountered in the Evolution group predominantly consisted of right ventricular injuries (*Table [3](#euaa103-T3){ref-type="table"}*). One case of injury to the right atrium and adjacent intrapericardial superior vena cava (SVC) occurred, and one late haemothorax requiring percutaneous drainage (*Table [3](#euaa103-T3){ref-type="table"}*) but no acute injuries to the extrapericardial part of the SVC were encountered.

Discussion
==========

The PROMET study is the largest study to report on efficacy and safety outcomes in patients undergoing mechanical TLE and is comparable in size to the largest series of laser extraction (*Table [4](#euaa103-T4){ref-type="table"}*). The key findings are:

###### 

Comparison of the results of the PROMET study with other published large volume studies

                  Patients/leads   Indications            Leads                   Implant duration (months)   Success rates   Major complications   In-hospital mortality
  --------------- ---------------- ---------------------- ----------------------- --------------------------- --------------- --------------------- -------------------------
  PROMET study    2205/3849        46.0% infection        74.8% pacemaker leads   Mean 84.7 ± 61.8            96.5% CPS       1%                    1.7% (30-day mortality)
                                   54.0% non-infectious   24.6% ICD leads         Median 74.0                 97.0%                                 
                                                          0.6% unknown            IQR (41.0--112.0)           CS                                    
  LEXICON study   1449/2405        56.9%                  70.0% pacemaker leads   Median 82.1                 96.5% CPS       1.4%                  1.86%
                                   Infection              29.2% ICD leads         IQR (0.4--356.8)            97.7%                                 
                                   43.1%                  0.7% unknown                                        CS                                    
                                   Non-infectious                                                                                                   
  ELECTRa study   3510/4917        52.8% infection        75.7% pacemaker leads   Mean 76.8 ± 64.8            95.7% CPS       1.7%                  1.4%
                                   47.3% non-infectious   24.3% ICD leads         Median 60.0                 96.7%                                 
                                                                                  IQR (24.0--108.0)           CS                                    

CPS, complete procedural success; CS, clinical success; ICD, implantable cardioverter-defibrillator; IQR, interquartile range.

1.  Mechanical tools can deliver a level of efficacy that is equivalent to that of laser powered sheaths.

2.  The use of mechanical tools is associated with a low procedural risk for major and minor complications. The nature of major complications differs from that reported in any of the large series describing laser-based TLE methods, particularly the lower incidence of procedural injuries to the SVC.

Safety
------

The list of adverse events encountered in the PROMET cohort is remarkable for the low incidence of acute injuries to the SVC, which, in contrast, account for most of the fatal complications of laser TLE.

The low incidence of injury to the SVC demonstrated in the PROMET study constitutes a major advance in TLE. Even in the expert hands represented by the LEXICON and ELECTRa investigators, vascular tears/avulsion occurred in 6/1449 and 20/3510 cases, respectively. In real-world practice, this complication has clinical relevance, demonstrated by two published series of SVC events in the context of the use of compliant endovascular occlusion balloon: the initial series reported 35 surgically confirmed cases of laser-related SVC disruption in the USA during a 6-month period and the follow-up series reported 116 SVC events in a 25-month period.[@euaa103-B15]^,^[@euaa103-B16] Even the lower of these estimates implies an average of more than 4 SVC events per month.

The reported safety results of the PROMET study are in line with the just recently published data of Diaz *et al*.,[@euaa103-B4] who compared the observed mortality between laser and rotational extraction sheaths based on the Manufacturer and User Facility Device Experience database. At different market share estimates and with adjustment for potential underreporting in cases with rotational sheaths the relative risk for mortality was significantly higher in laser sheath extractions than in procedures with the use of a rotational extraction sheath.

Efficacy
--------

The clinical success rate and complete procedural success rates for leads targeted for removal in the PROMET series compare favourably with other large patient cohorts in TLE procedures such as the Lexicon study[@euaa103-B3] and the ELECTRa registry.[@euaa103-B17] The efficacy of the Evolution rotational TLE device was proven by the achievement of complete procedural success in more than 95% of leads with median implant durations of 106 months, substantially longer than in previous large TLE studies.[@euaa103-B3]^,^[@euaa103-B17]

Limitations
-----------

The major limitation of this study is its retrospective study design. The acquired data represents real-world data in a number of centres in different nations over a period of just over a decade. Due to the retrospective design and the individual data recording in the different participating centres, data recording may not have been complete in all cases. Despite this fact, the authors believe that this data is of relevant clinical importance for the lead extraction community and supports the hypothesis of a satisfactory safety profile and high efficacy of rotational extraction sheaths, as seen in previous smaller series.[@euaa103-B6]^,^[@euaa103-B8]^,^[@euaa103-B10]^,^[@euaa103-B11]^,^[@euaa103-B18]

Conclusions
===========

This large series of cases show that an extraction service based on rotational dissecting tools can deliver a procedural mortality rate of \<0.2%, and that a service based on these products can deliver complete lead extraction in over 96% of leads targeted. In this series, rotational TLE tools showed a low incidence of major complications, especially of SVC injuries. The efficacy of rotational TLE tools was proven by the achievement of high success rates in leads with long implant durations.
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